Who makes Cohort 1, Ceplene® and Proleukin®?

Cohort 1, Ceplene® and Proleukin® is developed by Vastra Gotaland Region.

What development phase is Cohort 1, Ceplene® and Proleukin® in?

Cohort 1, Ceplene® and Proleukin® is in Phase 1.

Last reviewed 2026-05-15 · How we verify

Cohort 1, Ceplene® and Proleukin®

Vastra Gotaland Region · Phase 1 active Small molecule

At a glance

Generic name	Cohort 1, Ceplene® and Proleukin®
Sponsor	Vastra Gotaland Region
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

A Study of HDC/IL-2 Treatment in Chronic Myelomonocytic Leukemia (CMML) (PHASE1, PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Cohort 1, Ceplene® and Proleukin® CI brief — competitive landscape report
Cohort 1, Ceplene® and Proleukin® updates RSS · CI watch RSS
Vastra Gotaland Region portfolio CI